 |
|
|
| |
FINDINGS FROM CLINICAL VIROLOGY STUDIES ON ACH-3102 ARE CONSISTENT WITH PRECLINICAL OBSERVATIONS ON ITS IMPROVED POTENCY AGAINST GENOTYPE-1A HCV AND RESISTANT VARIANTS
|
| |
| |
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
Guangwei Yang, Dharaben Patel, Yongsen Zhao, Joanne Fabrycki, Wengang Yang, Steven Podos, Heather Robison, Lisa Robarge,
Hetal Kocinsky, James Hui, Milind Deshpande and Mingjun Huang
Achillion Pharmaceuticals, Inc., New Haven, CT
Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV
http://www.natap.org/2013/HCV/041613_04.htm
|
| |
|
|
|
|
|
